دورية أكاديمية
أعرض في EDS

Update on Hepatitis C Vaccine: Results and Challenges.

التفاصيل البيبلوغرافية
العنوان: Update on Hepatitis C Vaccine: Results and Challenges.
المؤلفون: Garbuglia AR; Laboratory of Virology, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), 00149 Rome, Italy., Pauciullo S; Laboratory of Virology, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), 00149 Rome, Italy., Zulian V; Laboratory of Virology, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), 00149 Rome, Italy., Del Porto P; Department of Biology and Biotechnology 'Charles Darwin', Sapienza University of Rome, 00100 Rome, Italy.
المصدر: Viruses [Viruses] 2024 Aug 21; Vol. 16 (8). Date of Electronic Publication: 2024 Aug 21.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Hepacivirus*/immunology , Hepacivirus*/genetics , Viral Hepatitis Vaccines*/immunology , Hepatitis C*/prevention & control , Hepatitis C*/immunology , Hepatitis C*/virology , Antibodies, Neutralizing*/immunology, Humans ; T-Lymphocytes/immunology ; Hepatitis C Antibodies/immunology ; Animals
مستخلص: Therapy against the Hepatitis C virus (HCV) has significantly improved with the introduction of direct-acting antiviral drugs (DAAs), achieving over 95% sustained virological response (SVR). Despite this, the development of an effective anti-HCV vaccine remains a critical challenge due to the low number of patients treated with DAAs and the occurrence of HCV reinfections in high-risk groups. Current vaccine strategies aim to stimulate either B-cell or T-cell responses. Vaccines based on E1 and E2 proteins can elicit broad cross-neutralizing antibodies against all major HCV genotypes, though with varying efficiencies and without full protection against infection. In humans, the neutralizing antibodies induced by such vaccines mainly target the AR3 region, but their levels are generally insufficient for broad neutralization. Various HCV proteins expressed through different viral vectors have been utilized to elicit T cell immune responses, showing sustained expansion of HCV-specific effector memory T cells and improved proliferation and polyfunctionality of memory T cells over time. However, despite these advancements, the frequency and effectiveness of T-cell responses remain limited.
References: J Hepatol. 2020 Apr;72(4):670-679. (PMID: 31785346)
Sci Rep. 2016 May 19;6:26296. (PMID: 27192960)
J Exp Med. 2003 Jun 16;197(12):1645-55. (PMID: 12810686)
Gastroenterology. 2017 Nov;153(5):1392-1403.e2. (PMID: 28780074)
Gastroenterology. 2019 Jun;156(8):2149-2157. (PMID: 30878469)
J Gen Virol. 2004 Jan;85(Pt 1):31-37. (PMID: 14718617)
J Virol. 2007 Aug;81(15):8101-11. (PMID: 17522218)
J Virol. 2014 Sep;88(18):10459-71. (PMID: 24965471)
Cells. 2019 Apr 03;8(4):. (PMID: 30987134)
Sci Rep. 2018 Apr 24;8(1):6483. (PMID: 29691437)
Sci Transl Med. 2012 Jan 4;4(115):115ra1. (PMID: 22218690)
N Engl J Med. 2021 Feb 11;384(6):541-549. (PMID: 33567193)
J Virol. 2022 Jun 22;96(12):e0052322. (PMID: 35612312)
BMC Infect Dis. 2011 Jan 12;11:15. (PMID: 21226945)
J Virol. 2009 Jun;83(11):5760-4. (PMID: 19321623)
BMC Infect Dis. 2021 Nov 3;21(1):1133. (PMID: 34732154)
PLoS Pathog. 2013;9(6):e1003422. (PMID: 23818845)
J Biol Chem. 2020 May 22;295(21):7179-7192. (PMID: 32299914)
J Hepatol. 2010 Mar;52(3):315-21. (PMID: 20129690)
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. (PMID: 28404132)
Annu Rev Immunol. 2019 Apr 26;37:457-495. (PMID: 30676822)
J Virol. 1993 Jul;67(7):3923-30. (PMID: 7685404)
Curr Opin Immunol. 2022 Aug;77:102209. (PMID: 35598506)
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30. (PMID: 17392433)
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294-8. (PMID: 7509068)
J Hepatol. 2014 Nov;61(1 Suppl):S14-25. (PMID: 25443342)
Hepatology. 2017 Apr;65(4):1117-1131. (PMID: 27997681)
N Engl J Med. 1995 Jun 1;332(22):1463-6. (PMID: 7739682)
Sci Rep. 2019 Sep 16;9(1):13300. (PMID: 31527718)
Hepatology. 2016 Dec;64(6):1881-1892. (PMID: 27351277)
Hepatology. 2022 Oct;76(4):1190-1202. (PMID: 35313015)
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):200-210. (PMID: 28404135)
Gastroenterology. 2014 Feb;146(2):550-61. (PMID: 24148617)
Cold Spring Harb Perspect Med. 2021 Mar 1;11(3):. (PMID: 32341067)
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10039-10047. (PMID: 31040211)
Hepatology. 2013 Jul;58(1):428-38. (PMID: 23467911)
Front Cell Infect Microbiol. 2021 Aug 03;11:712105. (PMID: 34414132)
Virol J. 2018 Mar 2;15(1):40. (PMID: 29499724)
Biochim Biophys Acta. 2016 Aug;1860(8):1764-75. (PMID: 26278021)
Epidemiol Infect. 2009 Sep;137(9):1255-65. (PMID: 19224654)
J Viral Hepat. 2020 Apr;27(4):449-452. (PMID: 31749225)
Hepatology. 2014 Jan;59(1):318-27. (PMID: 24115039)
J Virol. 2018 May 14;92(11):. (PMID: 29540595)
Gastroenterology. 2010 Sep;139(3):965-74. (PMID: 20621699)
PLoS One. 2013;8(3):e59776. (PMID: 23527266)
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8427-32. (PMID: 17485666)
J Virol. 2019 Jun 28;93(14):. (PMID: 31068427)
Open Forum Infect Dis. 2020 Apr 02;7(5):ofaa115. (PMID: 32391403)
Gastroenterology. 2007 Feb;132(2):667-78. (PMID: 17258731)
Eur J Immunol. 2015 Jul;45(7):2154-7. (PMID: 25824697)
Front Immunol. 2018 Jun 11;9:1315. (PMID: 29951061)
Nat Immunol. 2017 May 18;18(6):612-621. (PMID: 28518156)
Hepatology. 2000 Jul;32(1):91-6. (PMID: 10869294)
Open Forum Infect Dis. 2019 Feb 22;6(3):ofz076. (PMID: 30949527)
Vaccine. 2017 Dec 15;35(50):6949-6956. (PMID: 29089195)
J Infect Dis. 2011 Sep 1;204(5):811-3. (PMID: 21788452)
Curr Opin Virol. 2021 Aug;49:92-101. (PMID: 34091143)
Clin Gastroenterol Hepatol. 2010 Nov;8(11):924-33; quiz e117. (PMID: 20713178)
J Virol. 2005 May;79(10):6023-34. (PMID: 15857988)
J Viral Hepat. 2019 Sep;26(9):1105-1116. (PMID: 31074195)
Liver Int. 2012 Feb;32(2):339-45. (PMID: 22142261)
Int J Mol Sci. 2017 Dec 22;19(1):. (PMID: 29271914)
J Virol. 2019 Mar 21;93(7):. (PMID: 30651366)
Gastroenterology. 2010 Jan;138(1):315-24. (PMID: 19782080)
J Virol. 2007 Aug;81(15):8072-9. (PMID: 17507469)
J Virol. 2011 Nov;85(22):11833-45. (PMID: 21900166)
Hepatology. 2008 Oct;48(4):1044-53. (PMID: 18802961)
J Immunol. 2008 Nov 1;181(9):6435-46. (PMID: 18941234)
J Hepatol. 2015 Jan;62(1):31-40. (PMID: 25131771)
Gastroenterology. 2011 Oct;141(4):1422-31, 1431.e1-6. (PMID: 21763239)
Sci Adv. 2020 Apr 15;6(16):eaaz6225. (PMID: 32494617)
Hepatology. 2005 Oct;42(4):962-73. (PMID: 16149085)
Viruses. 2021 May 05;13(5):. (PMID: 34063143)
Hepatology. 2006 Mar;43(3):592-601. (PMID: 16496330)
Int J Pharm. 2000 Jan 20;194(1):39-49. (PMID: 10601683)
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15394-9. (PMID: 8986822)
Antiviral Res. 2015 Feb;114:96-105. (PMID: 25433310)
Hepatology. 2005 Jul;42(1):104-12. (PMID: 15962289)
J Clin Invest. 2021 Jan 19;131(2):. (PMID: 33463551)
Nat Rev Microbiol. 2007 Jun;5(6):453-63. (PMID: 17487147)
J Infect Dis. 2018 Oct 20;218(11):1722-1729. (PMID: 29982508)
Sci Transl Med. 2012 Jan 4;4(115):115ra2. (PMID: 22218691)
Nat Biotechnol. 1999 Nov;17(11):1075-81. (PMID: 10545912)
Science. 2003 Oct 24;302(5645):659-62. (PMID: 14576438)
Nat Rev Immunol. 2017 Nov;17(11):703-717. (PMID: 28757603)
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451-5. (PMID: 1848704)
Hum Vaccin. 2009 Mar;5(3):151-7. (PMID: 19246990)
J Exp Med. 2012 Jan 16;209(1):61-75. (PMID: 22213804)
Liver Int. 2007 Apr;27(3):335-9. (PMID: 17355454)
Gastroenterology. 2014 May;146(5):1351-60.e1-4. (PMID: 24486950)
Vaccines (Basel). 2019 Dec 03;7(4):. (PMID: 31816920)
J Virol. 2010 Jun;84(12):6218-28. (PMID: 20375170)
J Virol. 2008 Apr;82(7):3555-60. (PMID: 18234789)
Sci Transl Med. 2011 Aug 3;3(94):94ra71. (PMID: 21813755)
PLoS Pathog. 2012;8(4):e1002653. (PMID: 22511875)
Nat Med. 2006 Feb;12(2):190-7. (PMID: 16462801)
Nat Commun. 2022 Nov 25;13(1):7271. (PMID: 36434005)
J Virol. 2011 Oct;85(20):10451-63. (PMID: 21813602)
J Infect Dis. 2020 Mar 28;221(8):1304-1314. (PMID: 31074790)
J Infect Dis. 2011 Oct 15;204(8):1186-90. (PMID: 21917891)
J Hepatol. 2018 Jul;69(1):182-236. (PMID: 29628281)
Gastroenterology. 2020 Mar;158(4):1058-1071.e6. (PMID: 31809725)
Recent Pat Drug Deliv Formul. 2009 Nov;3(3):206-20. (PMID: 19534669)
Nature. 2005 Aug 18;436(7053):961-6. (PMID: 16107836)
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8449-54. (PMID: 17494735)
Sci Rep. 2019 Jun 25;9(1):9251. (PMID: 31239471)
Viruses. 2011 Nov;3(11):2127-45. (PMID: 22163337)
Gastroenterology. 2016 Mar;150(3):696-706.e3. (PMID: 26584604)
Front Immunol. 2018 Apr 27;9:910. (PMID: 29755477)
J Virol. 2002 Apr;76(8):4034-43. (PMID: 11907242)
J Exp Med. 2001 Nov 19;194(10):1395-406. (PMID: 11714747)
Hepatology. 2006 Nov;44(5):1355-61. (PMID: 17058236)
J Viral Hepat. 2009 Dec;16(12):833-43. (PMID: 19889142)
J Virol. 2011 May;85(9):4246-57. (PMID: 21325403)
HIV Med. 2018 Jul;19(6):420-425. (PMID: 29573533)
Science. 2013 Nov 29;342(6162):1090-4. (PMID: 24288331)
Value Health. 2022 Jul;25(7):1107-1115. (PMID: 35272954)
J Clin Invest. 2019 Aug 13;129(11):4786-4796. (PMID: 31408439)
Acta Gastroenterol Belg. 2021 Oct-Dec;84(4):637-656. (PMID: 34965046)
Curr Opin Immunol. 2015 Jun;34:130-6. (PMID: 25879814)
Gastroenterology. 2012 Oct;143(4):1048-60.e4. (PMID: 22705008)
Med Microbiol Immunol. 1992;181(5):293-300. (PMID: 1335546)
J Gen Virol. 2004 Jul;85(Pt 7):1853-1857. (PMID: 15218169)
Gut. 2018 Feb;67(2):372-379. (PMID: 27797937)
J Hepatol. 2024 Jul 8;:. (PMID: 38986744)
Gut. 2012 Aug;61(8):1226-34. (PMID: 21873736)
Nat Rev Immunol. 2016 Aug;16(8):509-23. (PMID: 27374637)
Sci Transl Med. 2014 Nov 5;6(261):261ra153. (PMID: 25378645)
J Virol. 2007 Sep;81(17):9584-90. (PMID: 17581991)
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15661-8. (PMID: 12441397)
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3468-72. (PMID: 1314389)
Biochimie. 2003 Mar-Apr;85(3-4):295-301. (PMID: 12770768)
J Virol. 2015 May;89(10):5478-90. (PMID: 25740982)
J Hepatol. 2016 Oct;65(4):719-726. (PMID: 27084592)
Hepatology. 2015 Jan;61(1):77-87. (PMID: 25069599)
J Virol. 1994 Mar;68(3):1494-500. (PMID: 8107212)
J Virol. 2010 Oct;84(19):9733-48. (PMID: 20660197)
N Engl J Med. 2014 May 15;370(20):1889-98. (PMID: 24725239)
Gastroenterology. 2013 Aug;145(2):447-55.e1-4. (PMID: 23673355)
Hepatology. 2013 Apr;57(4):1333-42. (PMID: 23172780)
Gastroenterology. 2011 Jun;140(7):2064-73. (PMID: 21376049)
Eur J Immunol. 2016 Sep;46(9):2204-10. (PMID: 27296288)
Hepatology. 2014 Jun;59(6):2140-51. (PMID: 24425349)
Nat Immunol. 2015 Nov;16(11):1114-23. (PMID: 26482978)
J Exp Med. 2016 Apr 4;213(4):469-81. (PMID: 27022144)
Hepatology. 2008 Aug;48(2):418-31. (PMID: 18563841)
Front Immunol. 2018 May 31;9:1194. (PMID: 29904384)
Hepatology. 2016 May;63(5):1430-41. (PMID: 26822022)
J Viral Hepat. 2018 Mar;25(3):220-227. (PMID: 29316030)
Vaccine. 2010 Aug 31;28(38):6367-73. (PMID: 20619382)
J Clin Microbiol. 2015 Mar;53(3):967-72. (PMID: 25520447)
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7537-41. (PMID: 19380744)
Gastroenterology. 2009 Jun;136(7):2377-86. (PMID: 19303013)
Int J Cancer. 2020 Jul 15;147(2):317-330. (PMID: 31597196)
Bioinformatics. 2005 Feb 1;21(3):379-84. (PMID: 15377502)
Blood. 2011 Jan 27;117(4):1250-9. (PMID: 21084709)
معلومات مُعتمدة: Ricerca Corrente, Linea Epatiti Ministero della Salute
فهرسة مساهمة: Keywords: hepatitis C; immune response; immunogenicity; neutralizing antibody; vaccine
المشرفين على المادة: 0 (Viral Hepatitis Vaccines)
0 (Antibodies, Neutralizing)
0 (Hepatitis C Antibodies)
تواريخ الأحداث: Date Created: 20240829 Date Completed: 20240829 Latest Revision: 20240903
رمز التحديث: 20240903
مُعرف محوري في PubMed: PMC11359353
DOI: 10.3390/v16081337
PMID: 39205311
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4915
DOI:10.3390/v16081337